Skip to main content
Caplight Logo









MindImmune Therapeutics, Inc.

MindImmune Therapeutics, Inc.

Private
Kingston, Rhode IslandHealthcare & Life Scienceshttps://mindimmune.com

Last Round

Convertible Debt

Mar 5, 2026

Est. Valuation

$22.4M

Total Funding Raised

$52.97M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

MindImmune Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in Kingston, Rhode Island. Its latest recorded funding round was a Convertible Debt round in March 2026.

MindImmune Therapeutics, Inc. is a biotechnology company that develops antibody-based drugs and therapeutics designed to treat diseases of the central nervous system by targeting neuroinflammation.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

MindImmune Therapeutics, Inc. Comparables

Compare MindImmune Therapeutics, Inc. with similar companies based on industry and business-model similarity.

MindImmune Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Monument Biosciences
84%
CuraSen Therapeutics, Inc.
81%
Muna Therapeutics
80%
Book a demo to see all comparables

For institutional investors. Book with your work email.

MindImmune Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtMar 5, 2026
Series ANov 24, 2025
GrantJun 1, 2025
Series AJun 14, 2022
GrantJan 1, 2022
Early Funding
Oct 22, 2019
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Isaac Stoner

Chief Executive Officer, Board Member

Executive Team

Stevin Zorn

President, CEO, Co-Founder

Founding Team

For institutional investors. Book with your work email.

MindImmune Therapeutics, Inc. Investors

Notable investors and investment history

MindImmune Therapeutics, Inc. investors
InvestorRounds
Dolby Family VenturesSeries A
Rhode Island Life Science HubGrant
The Foundation For A Better WorldSeries A
Pfizer VenturesSeries A
RightHill VenturesSeries A
PfizerSeries A
Slater Technology FundSeries A, Seed
Book a demo to see all 10 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 61% MoM, from 1.4K to 2.3K.

  • Mar 5, 2026

    Raised $5M in a VC Round.

Book a demo to see all signals

For institutional investors. Book with your work email.

MindImmune Therapeutics, Inc. Filings

Explore SEC and related filing metadata, where available.

MindImmune Therapeutics, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about MindImmune Therapeutics, Inc.'s valuation, stock price, and market status.

Is MindImmune Therapeutics, Inc. a public or private company?

MindImmune Therapeutics, Inc. is a private company.

What is the current stock price of MindImmune Therapeutics, Inc.?

MindImmune Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks MindImmune Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is MindImmune Therapeutics, Inc. worth (valuation)?

MindImmune Therapeutics, Inc.'s valuation is estimated at $22.4M based on funding round data.

Can I buy MindImmune Therapeutics, Inc. stock?

MindImmune Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was MindImmune Therapeutics, Inc.'s last funding round?

MindImmune Therapeutics, Inc.'s most recent funding round was Convertible Debt on March 5, 2026.

Who are the main investors in MindImmune Therapeutics, Inc.?

Key investors in MindImmune Therapeutics, Inc. include Dolby Family Ventures, Slater Technology Fund, Alzheimer's Drug Discovery Foundation.

Will MindImmune Therapeutics, Inc. IPO soon?

No public IPO plans have been announced for MindImmune Therapeutics, Inc..

How can I track MindImmune Therapeutics, Inc. secondary market activity?

Caplight tracks bids, offers, and trades in MindImmune Therapeutics, Inc.'s shares on secondary markets.

Firmographic Details

HeadquartersKingston, Rhode Island
Employee Range14
Year Founded2016
Last FundingMar 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?